ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Dear All:Starting to get caught up after some time on vacation! For today, we have announcement by CARB-X of the posting of two openings for the role of Assistant Directors of External Affairs. Here are the links:Official webpage: https://jobs.silkroad.com/BU/External/jobs/316699LinkedIn post: https://www.linkedin.com/posts/damianodefelice_job-opportunity-vacancy-share-7461081369562066944-tS7OA few excerpts from the job description:"The Assistant Director of External Affairs will play a pivotal role in strengthening CARB-X’s financial sustainability and elevating its partnerships and impact across the global antimicrobial innovation ecosystem.""Reporting to the Director of External Affairs (Will Hall), these positions offer the opportunity to help shape and execute CARB-X’s engagement strategy with funders, policy-makers and innovation partners worldwide."Required skill set: "8+ years of experience demonstrating strong fundraising capability and relationship cultivation."Location: The position "can be entirely virtual but must be able to work (at least partially) in ET and CET time zones."The deadline to apply for these positions is Wednesday, 3 June 2026.These are great opportunities for the right folks! Could you be one of the two people appointed to these exciting roles? All best wishes, --jrJohn H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All...
Dear All (and with thanks...
Dear All:ESCMID Global once again...
Dear All:I've just learned of...
Dear All (and with thanks...
Latest Government Action
Dear All,No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is that I heard a fascinating talk on the idea of "regulatory sandboxes" during the recent BEAM-AMR meeting. I had not previously heard of this idea, but it turns out that the concept of regulatory sandbox has been around for some years in the financial world with the idea being that of “a ‘safe space’ in which businesses can test innovative products, services, business models and delivery mechanisms without immediately incurring all the normal regulatory consequences of engaging in the activity in question.” So, it then turns out that the European Commission (EC) began a few years ago to consider the idea of using regulatory sandboxes to explore areas where scientific advances were struggling to progress due to a mismatch between the science and the current regulatory frameworks. The online information on this is currently somewhat scattered, but here are some links to get you started:9 Dec 2025: https://gdprlocal.com/eu-regulatory-sandbox/: An excellent introductory blog16 Dec 2025: A Q&A document regarding the European Biotech Act that alludes to sandboxes as as controlled environments for companies to experiment and trial innovative solutions, regulatory procedures and technologiesJuly 2025: A...
Dear All,There are more details...
Dear All (and with thanks...
Dear All,Referring back to the...
Dear All,Attention phage developers --...
Dear All,D-Day and the momentous Normandy...
R&D Insight
Dear All, Sadly, I must...
Note: See also these related...
Dear All: Two updates today. First, our...
Dear All: The new Novo...
Dear All, The BEAM Alliance, along...
Aside: Please look closely at...
Can you help?
Dear All,I have just learned that Lifeline, the musical formerly known as The Mould that Changed the World, is seeking scientists, medics, and healthcare professionals to be part of the cast for a portion of a planned 5-week off-Broadway run of the show around the time of the High-Level Meeting (HLM) on AMR at UNGA 2024 in New York City...
Dear All, Heads up! Having...
Note: Be sure to take...
Update on 11 October 2023: The...
Dear All,Along with more than...
Dear All (and with thanks to...
Dear All, Two items for...
Dear All, Three things today......
Dear All, Greetings from ECCMID...
Dear All,A key theme of...
Dear All,Following hard on the...
Dear All, A short one...
Dear All, We are swimming...
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
AMR Fireside Chats
1/19 videos
1
Episode 18 w/Robin Hiley- Fireside Chat
19:48
2
Episode 17 w/ Ella Balasa and Rob Purdie of WHO Task Force of AMR Survivors - AMR Fireside Chat
38:24
3
Episode 16 w/ Ramanan Laxminarayan, PhD - AMR Fireside Chat
32:59
4
Episode 15 w/ Mark Albrecht, PhD - AMR Fireside Chat
43:55
5
Episode 14 w/ Lynn Silver - AMR Fireside Chat
56:23
6
Episode 13 w/ Kevin Outterson - AMR Fireside Chat
30:01
7
Episode 12 w/ Tina Joshi, PhD - AMR Fireside Chat
34:22
8
Episode 11 w/ Martin Heidecker - AMR Fireside Chat
32:31
9
Episode 10 w/ Anna Govett - AMR Fireside Chat
14:54
10
Episode 9 w/ Fatema Rafiqi, PhD - AMR Fireside Chat
34:10
11
Episode 8 w/ Ghada Zoubiane, PhD - AMR Fireside Chat
35:04
12
Episode 7 w/ Trevor Lithgow, PhD - AMR Fireside Chat
35:41
13
AMR Snapshots: Episode 2 - John Rex (Editor-In-Chief, AMR.Solutions)
26:25
14
Episode 6 w/ Maryn McKenna - AMR Fireside Chat
45:50
15
Episode 5 w/ Christine Årdal - AMR Fireside Chat
43:44
16
Episode 4 w/ Peter Beyer - AMR Fireside Chat
39:21
17
Episode 3 w/ Kevin Outterson - AMR Fireside Chat
11:45
18
Episode 2 w/ Henry Skinner, PhD - AMR Fireside Chat
15:44
19
Episode 1 w/ Kevin Outterson - AMR Fireside Chat
52:56
Public meeting on the LPAD Pathway: Post-meeting thoughts (wonkish)
Long and wonkish note alert — please refresh your coffee before you start reading! Dear All: I was able to attend and speak at the ...
Read More →
Lancet: 10-20-30 targets to address AMR by 2030
Dear All (wonkish alert … but definitely worth the effort! Refill your coffee!),Ramanan Laxminarayan and about 40 colleagues from around the world have just published in ...
Read More →
Draft FDA guidance on anti-infectives for children: It’s (mostly) all about PK and safety
Dear All (wonkish alert … the first 3 segments are non-wonkish but the last 2 are in the wonkish zone … titrate your plasma caffeine ...
Read More →
Scary, Scarier, Scariest (Part 2): What can YOU do about it?
Long note alert— apologies! Get a cup of coffee and settle in… Dear All: My 22 Apr 2019 note entitled Scary, Scarier, Scariest: Achaogen / FT ...
Read More →
NIAID workshop: What is a robust PK-PD package?
Dear All: The ~150 of us who gathered in Washington yesterday and today for the NIAID’s PK-PD workshop enjoyed a very rich conversation. It’s really ...
Read More →
How hard (and how) to Pull? Net value of Pull via a Transferrable Exclusivity Extension (TEE)
Dear All (wonkish alert … get your coffee!), EFPIA have recently released a report estimating the value of a Transferable Exclusivity Extension (TEE, report, press ...
Read More →
Plazomicin EU marketing application is withdrawn: Near zero market value of newly approved antibacterials
Dear All (with thanks to Kevin Outterson for co-authoring this newsletter), Last week’s announcement of the AMR Action Fund was both exciting and sobering: $1b ...
Read More →
The 6 meanings of “Lack of Access” (UNSLAP)
Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year ...
Read More →
FDA and EMA regulatory updates / Fireside chat during the 4th AMR Conference
Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug 2020 BEAM Alliance-sponsored AMR Conference ...
Read More →
UK to expand NHS Subscription Pilot! Consultation Period launches
Dear All (and with thanks to Kevin for co-authoring), The UK NHS England Pilot is known to us all as the first real attempt at an antibiotic ...
Read More →
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
Note: See also these related newsletters: 13 Jan 2019 on DTR as part of the language of resistance, 7 Jun 2020 on using DTR to estimate ...
Read More →
DTR Gram-negative infections: Are new antibiotics making a difference?
Dear All (and with thanks to Aaron Dane for co-authoring this newsletter AND inhale, exhale … this is going to be a long, wonkish, but VERY ...
Read More →
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
Summaries
Notes: Newsflash ... BARDA have...
Aside: If you've enjoyed the...
See also This related newsletter:...
Dear All (and with thanks...
Dear All (Wonkish alert! Coffee-up!),Today...